US lingerie company Victoria’s Secret has reached a settlement in a lawsuit over the sale of knockoff products that mimic the get-up of its trade marked body care products.
F. Hoffman La-Roche has reached a settlement in a patent lawsuit over Sandoz’s plan to market a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.
The takeover battle for Xenith IP has entered round two, with IPH submitting a revised proposal to acquire the IP services firm in full, leaving fellow suitor QANTM with three days to lodge a competing offer.
Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court’s decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.
A case simultaneously challenging IP Australia’s decisions to accept, grant and certify an innovation patent owned by one of Australia’s biggest building product companies has been withdrawn, a court has heard.
Melbourne-based pub and music venue The Corner Hotel has filed a trade mark lawsuit against a jazz club formed in partnership with iconic New York club Birdland, as it continues to do battle with McDonald’s for allegedly infringing its “Corner” trade marks.
The US International Trade Commission has opened an investigation into alleged patent infringement by solar companiesĀ JinkoSolar, LONGi Solar and REC Group, after Korean solar company Hanwha Q CELLS filed two related proceedings in Australian court alleging the companies are infringing its solar technology.
Bega Cheese has presuaded a court to allow a partner from Addisons Lawyers to access select confidential documents, expanding the confidentiality regime at the heart of its dispute with Fonterra Brands over an allegedly violated trade mark licence agreement.
Two generic pharmaceutical companies, Generic Partners and Apotex, have filed cross-claims alleging that Neurim Pharmaceuticals’ patent for its insomnia drug Circadin is invalid and should be revoked.
IP Australia has ordered biotech firm MacroGenics to amend its patent for a type of polypeptide used in treatments for cancer, autoimmune disorders and other diseases after a successful opposition from the chairman of intellectual property boutique Wrays.